How genes affect response to sitagliptin in Amish adults
Part of Hormones & metabolism clinical trials.
This trial is studying how your genes affect your response to sitagliptin, a drug that helps control blood sugar. It is open only to Old Order Amish adults in Lancaster, PA, who are generally healthy and do not have diabetes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must be a member of the Old Order Amish community in Lancaster, PA.
- You must not be pregnant (women who could become pregnant will have a pregnancy test before receiving the drug).
- You must not have diabetes — your blood sugar must be below the diabetes range (HbA1c 6.5% or less, fasting blood glucose 126 mg/dL or less).
- You must have healthy kidneys (eGFR 60 or more), not have anemia (hematocrit 35% or more), and have normal thyroid and liver function tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study looks at how genetic factors may change how people respond to a GLP-1 medicine (semaglutide). The goal is to learn who may benefit most and why, so future treatments can be better matched.
This study looks at how genetic risk relates to developing type 2 diabetes, using information from a biobank and body measurements like weight. It may help researchers better identify who is at higher risk before diabetes starts.
This study looks at how your genes may change how well a GLP-1–type medicine works to improve prediabetes. It focuses on adults at higher risk of developing diabetes, especially people of Mexican-American background.
This study looks at how your genes affect your body's response to a diabetes medication called semaglutide. It may help people with slightly high blood sugar (pre-diabetes) understand why some respond better than others.
This study tests whether the drug sitagliptin can delay or prevent type 1 diabetes in people who have a family member with the disease and show early signs of risk. If you are eligible, you would take sitagliptin and have regular health checks for about a year.
This study looks at how your genes might affect the way your body responds to metformin, a common diabetes medication. It aims to see if a specific genetic variation influences treatment outcomes.
Hear when a new Diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.